NCT06502431

Brief Summary

A global analysis of craniospinal hemodynamics and hydrodynamics is necessary to better understand the pathophysiology of Chiari malformations. This includes an analysis of intraventricular CSF flow, intracranial subarachnoid spaces, foramen magnum, cervical subarachnoid spaces and within the syringomyelia cavity when present. The investigators will also analyze the pulsatility of the cerebellar tonsils in the foramen magnum. Hemodynamic analysis will be performed at the high cervical level (internal carotid and vertebral arteries, jugular veins) and intracranially (carotid and basilar arteries, right sinus and superior longitudinal sinus). This analysis will be made possible by PCMRI acquisitions with slice planes allowing the analysis of the dynamics of the CSF (mesencephalic aqueduct, prepontic cisterns, foramen magnum, at the level of the C2C3 disc, syringomyelia if present), cerebellar tonsils (foramen magnum). The cross-sectional planes for hemodynamic analysis will be at the level of the C2C3 disc (cervical vascular analysis) and upstream of the polygon of Willis (intracranial vascular analysis). The goal is to complement the clinical and morphological investigations with quantitative imaging of cerebrospinal fluid (CSF) and blood flow in the craniospinal system. These flows are potentially altered or causes of this Chiari anomaly. The investigators propose a translational research project of clinical research allowing the analysis of a diagnostic technique by a diagnostic, monocentric, prospective study. After neurosurgical consultation, patients with Chiari malformation will be assigned to a symptomatic Chiari malformation or a non-symptomatic Chiari malformation group. They will be offered to participate in this study after information and informed consent. The allocation between the two groups will be made according to the symptomatic or non-symptomatic nature of the Chiari malformation. After inclusion, the patients will have a morphological MRI and a PCMRI according to the determined slice plans and allowing a global analysis of the craniospinal hemohydrodynamics. Craniospinal hemohydrodynamics in a control population will also be analyzed using the same methodology by PCMRI.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
14mo left

Started Jun 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress63%
Jun 2024Jul 2027

Study Start

First participant enrolled

June 24, 2024

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

July 9, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 16, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
2.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Expected
Last Updated

April 2, 2025

Status Verified

April 1, 2025

Enrollment Period

9 months

First QC Date

July 9, 2024

Last Update Submit

April 1, 2025

Conditions

Keywords

Type I Chiari MalformationCerebral hemodynamicCraniospinal hydrodynamicPhase contrast MRICerebrospinal fluid

Outcome Measures

Primary Outcomes (2)

  • CSF Flow

    Flow will be measured by the oscillatory volume expressed in mL/cardiac cycle.

    day 1

  • Blood Flow

    Flow will be measured by the oscillatory volume expressed in mL/cardiac cycle.

    day 1

Study Arms (3)

Symptomatic CMI group

EXPERIMENTAL
Other: phase contrast sequences

Non-Symptomatic CMI group

EXPERIMENTAL
Other: phase contrast sequences

Control group

ACTIVE COMPARATOR
Other: phase contrast sequences

Interventions

patients will benefit from phase contrast sequences complementary to the morphological MRI performed as part of the patient management.

Control groupNon-Symptomatic CMI groupSymptomatic CMI group

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • All patients with major symptomatic or nonsymptomatic CMI
  • aged 18 to 50 years
  • no previous neurosurgical, neurological, or cardiological history.
  • Controls should be age-matched to symptomatic CMI group. They should not have a history of neurosurgery, neurology, or cardiology.

You may not qualify if:

  • Patients who are minors or over 50 years of age
  • CMI invalidated by our radiological review
  • Neurosurgical, neurological or cardiological history
  • MRI contraindication
  • pregnant, breast-feeding and parturient women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Amiens Picardie

Amiens, Picardie, 80054, France

Location

MeSH Terms

Conditions

Arnold-Chiari Malformation

Condition Hierarchy (Ancestors)

Neural Tube DefectsNervous System MalformationsNervous System DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 9, 2024

First Posted

July 16, 2024

Study Start

June 24, 2024

Primary Completion

April 1, 2025

Study Completion (Estimated)

July 1, 2027

Last Updated

April 2, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations